IO Biotech, Inc.
IOBT
$1.72
$0.010.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.35% | 2.30% | 0.33% | 4.98% | 2.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.21% | 4.11% | 4.08% | 15.26% | 22.84% |
| Operating Income | -6.21% | -4.11% | -4.08% | -15.26% | -22.84% |
| Income Before Tax | -18.06% | -11.01% | -10.34% | -13.38% | -21.35% |
| Income Tax Expenses | 30.58% | 36.35% | 69.37% | -9.08% | -65.54% |
| Earnings from Continuing Operations | -18.16% | -11.25% | -10.93% | -12.96% | -18.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.16% | -11.25% | -10.93% | -12.96% | -18.95% |
| EBIT | -6.21% | -4.11% | -4.08% | -15.26% | -22.84% |
| EBITDA | -6.22% | -4.09% | -4.05% | -15.28% | -22.83% |
| EPS Basic | -9.70% | 19.65% | 32.77% | 44.15% | 43.96% |
| Normalized Basic EPS | -9.39% | 19.68% | 32.88% | 43.66% | 42.72% |
| EPS Diluted | -9.70% | 19.65% | 32.77% | 44.15% | 43.96% |
| Normalized Diluted EPS | -9.39% | 19.68% | 32.88% | 43.66% | 42.72% |
| Average Basic Shares Outstanding | 6.34% | 25.04% | 51.73% | 92.90% | 115.00% |
| Average Diluted Shares Outstanding | 6.34% | 25.04% | 51.73% | 92.90% | 115.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |